Allogene Therapeutics, Inc.
$2.06
The Read: Allogene’s stock surged about 51% after confirming a stable cash runway through mid-2027 and meeting EPS estimates, but then dropped about 17% when it raised expense guidance and lost a key Asian cell therapy partner despite positive clinical data.
ALLO
Hover to view data
No Data